Coherus Oncology (CHRS) EV to EBIT (2014 - 2026)

Coherus Oncology has disclosed EV to EBIT across 13 years of filings, most recently posting 3.43 for Q2 2026.

• In Q2 2026, EV to EBIT fell 202.16% year-over-year to 3.43; the TTM figure through Jun 2026 stood at 0.7 (down 183.81% YoY), while the FY2025 annual figure was 0.0, up 100.28% from the prior year.
• EV to EBIT came in at 3.43 for Q2 2026 at Coherus Oncology, down from 2.59 in the prior quarter.
• In the past five years, EV to EBIT ranged from a high of 3.36 in Q2 2025 to a low of 8.65 in Q3 2023.
• Average EV to EBIT over 5 years is 3.35, with a median of 3.01 recorded in 2026.
• Year-over-year, EV to EBIT jumped 432.33% in 2025 and slumped 925.05% in 2026.
• Over 5 years, EV to EBIT stood at 8.41 in 2022, then jumped by 55.81% to 3.71 in 2023, then jumped by 80.09% to 0.74 in 2024, then jumped by 100.25% to 0.0 in 2025, then plunged by 185309.25% to 3.43 in 2026.
• Per Business Quant data, the three most recent EV to EBIT figures were 3.43 in Q2 2026, 2.59 in Q1 2026, and 0.0 in Q4 2025.